Dare Bioscience
DARE
21 hedge funds and large institutions have $2.22M invested in Dare Bioscience in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
38% more capital invested
Capital invested by funds: $1.61M → $2.22M (+$608K)
11% more funds holding
Funds holding: 19 → 21 (+2)
0.08% more ownership
Funds ownership: 0.51% → 0.59% (+0.08%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$661K |
| 2 |
Renaissance Technologies
New York
|
+$57.2K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$19.1K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$10.5K |
| 5 |
RFA
Reilly Financial Advisors
La Mesa,
California
|
+$7.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFS
Founders Financial Securities
Towson,
Maryland
|
-$52.8K |
| 2 |
VF
Virtu Financial
New York
|
-$24.5K |
| 3 |
ECM
ETrade Capital Management
Arlington,
Virginia
|
-$15K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$2.23K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.32K |
DARE Hedge Fund Activity: Q3 2020 in Review
21 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q3 2020, worth a combined $2.22M — up 38% from $1.61M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DARE positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $661K. The largest seller was Founders Financial Securities, cutting an estimated $52.8K.
- 21 institutional investors held Dare Bioscience (DARE) as of Q3 2020, up from 19 in Q2 2020.
- Funds reported $2.22M of Dare Bioscience stock for Q3 2020, up 38% quarter-over-quarter.
- 3 funds opened new Dare Bioscience positions in Q3 2020 and 1 closed out, a net change of +2 holders.
- The largest Dare Bioscience buyer in Q3 2020 was Vanguard Group, an estimated $661K added.
- The largest Dare Bioscience seller in Q3 2020 was Founders Financial Securities, an estimated $52.8K sold.
Based on aggregated 13F filings for Q3 2020.